Idenix Pharmaceuticals LLC v. Gilead Sciences Inc.
Petition for certiorari denied on January 19, 2021
Issue: (1) Whether, as the U.S. Court of Appeals for the Federal Circuit has held, a
genus claim is not enabled "as a matter of law" if
it encompasses a large number of compounds " or
whether, as the Supreme Court has recognized,
enablement is a context-specific jury question; and (2) whether, as the Federal Circuit has held,
SCOTUSblog Coverage
- Petitions of the week: Deadlines for attorneys fees, the elements of burglary and more (Andrew Hamm, October 23, 2020)
Date | Proceedings and Orders |
---|---|
09/21/2020 | Petition for a writ of certiorari filed. (Response due October 26, 2020) |
10/09/2020 | Waiver of right of respondent Gilead Sciences, Inc. to respond filed. |
10/14/2020 | DISTRIBUTED for Conference of 10/30/2020. |
10/16/2020 | Response Requested. (Due November 16, 2020) |
10/30/2020 | Motion to extend the time to file a response from November 16, 2020 to December 16, 2020, submitted to The Clerk. |
11/02/2020 | Motion to extend the time to file a response is granted and the time is extended to and including December 16, 2020. |
11/16/2020 | Brief amicus curiae of GLAXOSMITHKLINE PLC. filed. |
11/16/2020 | Brief amicus curiae of Intellectual Property Professors filed. |
11/16/2020 | Brief amicus curiae of Amgen Inc. filed. |
12/16/2020 | Brief of respondent Gilead Sciences, Inc. in opposition filed. |
12/30/2020 | DISTRIBUTED for Conference of 1/15/2021. |
12/30/2020 | Reply of petitioners Universita Degli Studi di Cagliari filed. (Distributed) |
01/19/2021 | Petition DENIED. |